Cymbalta News and Research RSS Feed - Cymbalta News and Research

Cymbalta is a drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor. Also called duloxetine and duloxetine hydrochloride.
BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. [More]
Research report on China's duloxetine market

Research report on China's duloxetine market

Research and Markets has announced the addition of the "Investigation Report on China Duloxetine Market" report to their offering. [More]
Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]
Research report on global pain management devices market

Research report on global pain management devices market

Research and Markets has announced the addition of the "Global Pain Management Devices Market Report 2013-2018 " report to their offering. [More]
Lilly Peers Into Future, Sees Three Drug Launches In 2014

Lilly Peers Into Future, Sees Three Drug Launches In 2014

... [More]
Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain. [More]
Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system completed a pharmacokinetic (PK) study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome. [More]
Eli Lilly third quarter total revenue increases 9% to $6.148 billion

Eli Lilly third quarter total revenue increases 9% to $6.148 billion

Eli Lilly and Company today announced financial results for the third quarter of 2011. [More]
First-ever comprehensive study of species origins of nature-derived drugs

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough. [More]
UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston. [More]

Lilly second quarter total revenue increases 9% to $6.253 billion

Eli Lilly and Company today announced financial results for the second quarter of 2011. [More]
Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain. [More]

Eli Lilly total revenue increases 6% to $5.839 billion for first quarter 2010

Eli Lilly and Company today announced financial results for the first quarter of 2011. [More]

Lilly fourth quarter worldwide total revenue increases 4% to $6.187 billion

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2010. [More]
Depression drug appears effective in reducing pain associated with breast cancer treatment

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center. [More]

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. [More]

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules. [More]
FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004. [More]

Eli Lilly 2010 third-quarter total revenue increases 2% to $5.655 billion

Eli Lilly and Company today announced financial results for the third quarter of 2010.Financial results for 2010 and 2009 are presented on both a reported and a non-GAAP basis. [More]
FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved. [More]